LineaRx
APDNPrivate Company
Total funding raised: $17M
Overview
LineaRx, a subsidiary of Applied DNA Sciences, Inc. (APDN), was founded in 2018 to commercialize over two decades of enzymatic DNA production expertise. Its mission is to overcome the critical bottleneck of plasmid DNA manufacturing by providing a faster, purer, and more scalable DNA production platform. The company's strategy is to function as a technology and product supplier, enabling partners across the biopharmaceutical industry to advance their therapeutic pipelines from research through commercial manufacturing.
Technology Platform
LinearDNA™: A proprietary, large-scale PCR-based, cell-free enzymatic platform for producing high-purity, sequence-defined therapeutic DNA as an alternative to traditional plasmid DNA manufacturing.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
LineaRx competes with established plasmid DNA CMOs (e.g., Aldevron, Charles River) and alternative enzymatic platforms like Rolling Circle Amplification (RCA). Its differentiation lies in its proven, scalable PCR process that yields 100% target sequence DNA, offering superior speed, purity, and flexibility compared to these incumbents and alternatives.